Adpkd
Tolvaptan may slow eGFR decline in patients with autosomal dominant PKD
Routine use of tolvaptan in clinical practice may slow eGFR decline for patients with autosomal dominant polycystic kidney disease compared with historical controls, data show.
Autosomal dominant PKD registry may help assess disease burden in patients with CKD
The autosomal dominant polycystic kidney disease registry may help assess various aspects of disease burden on patients’ health-related quality of life, according to published research.
FDA grants orphan drug designation to AP303 for autosomal dominant PKD
The FDA has granted orphan drug designation to AP303 for the treatment of autosomal dominant polycystic kidney disease.
Outcomes reported by adults with autosomal dominant PKD predicted hospitalizations
Patient-reported outcome scores effectively predicted clinical and health-economic outcomes in adults with autosomal dominant polycystic kidney disease, a study found.
Be Proactive, Not Reactive: Updated Strategies for Optimal ADPKD Management and Better Outcomes
This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.